Sadiya Khan At the policy level, Khan et al highlighted issues around high out-of-pocket costs, restrictions placed on the ...

Labels of all GLP-1 receptor agonists now carry a warning about pulmonary aspiration during general anesthesia or deep ...

A new Northbrook pharma will work to bring its obesity treatment to market that it says holds advantages over Ozempic and its ...

Wegovy manufacturer Ascendis Pharma has been tasked with supporting the development of a once-monthly GLP-1 drug.

[5] Dulaglutide: A type of glucagon-like peptide-1 (GLP-1) receptor agonist approved by the U.S. Food and Drug Administration ...

Recently the U.S. Food and Drug Administration (FDA) issued updated safety warnings for all glucagon-like peptide 1 receptor ...

New research presented at the ACG Annual Meeting suggests that GLP-1RAs lower the risk of pancreatic cancer in patients with ...

Novo Nordisk has signed off on a $285 million biobucks deal with fellow Denmark-based company Ascendis Pharma to help the Wegovy manufacturer develop a once-monthly GLP-1 receptor agonist.

A new joint study by the University of Eastern Finland and Karolinska Institutet in Sweden found that the GLP-1 agonists ...

In a deal worth up to $285 million initially for the lead program, Novo Nordisk will gain access to Ascendis’ TransCon ...

Only 13 states currently allow Medicaid to cover treatment of obesity using glucagon-like peptide-1 agonist (GLP-1) medications, researchers said.

GLP-1 receptor agonists, originally developed for managing type 2 diabetes ... Perceived high costs, inconsistent insurance ...